T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer

Novel T-cell immunotherapies such as bispecific T-cell engagers (BiTEs) are emerging as promising therapeutic strategies for prostate cancer. BiTEs are engineered bispecific antibodies containing two distinct binding domains that allow for concurrent binding to tumor-associated antigens (TAAs) as we...

Full description

Saved in:
Bibliographic Details
Published in:Cancer biology & therapy 2024-12, Vol.25 (1), p.2356820-2356820
Main Authors: Palecki, Julia, Bhasin, Amman, Bernstein, Andrew, Mille, Patrick J., Tester, William J., Kelly, Wm. Kevin, Zarrabi, Kevin K.
Format: Article
Language:English
Subjects:
Animals
Antibodies, Bispecific - immunology
Antibodies, Bispecific - pharmacology
Antibodies, Bispecific - therapeutic use
Antigens, Neoplasm - immunology
Bispecific antibody
Humans
immunotherapy
Immunotherapy - methods
Male
Prostate cancer
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - immunology
Prostatic Neoplasms - pathology
Prostatic Neoplasms - therapy
PSMA
Review
STEAP1
T-Lymphocytes - immunology
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Novel T-cell immunotherapies such as bispecific T-cell engagers (BiTEs) are emerging as promising therapeutic strategies for prostate cancer. BiTEs are engineered bispecific antibodies containing two distinct binding domains that allow for concurrent binding to tumor-associated antigens (TAAs) as well as immune effector cells, thus promoting an immune response against cancer cells. Prostate cancer is rich in tumor associated antigens such as, but not limited to, PSMA, PSCA, hK2, and STEAP1 and there is strong biologic rationale for employment of T-cell redirecting BiTEs within the prostate cancer disease space. Early generation BiTE constructs employed in clinical study have demonstrated meaningful antitumor activity, but challenges related to drug delivery, immunogenicity, and treatment-associated adverse effects limited their success. The ongoing development of novel BiTE constructs continues to address these barriers and to yield promising results in terms of efficacy and safety. This review will highlight some of most recent developments of BiTE therapies for patients with advanced prostate cancer and the evolving data surrounding BiTE constructs undergoing clinical evaluation.
ISSN:1538-4047
1555-8576
DOI:10.1080/15384047.2024.2356820